Cagrilintide
Also known as: NN9838
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.
Who's worth your money for Cagrilintide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 13 scored sellers
$56.99 · 10mg · 99.9% purity
Most tested
8 independent COAs on file
$135 · 10mg · 99.3% purity
Average price
$13.63/mg
Sellers
66
45-day trend
-2.6%
53 of 66 sellers have a current price· 23 stale hidden· 17 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · 23h ago
$5.70/mg -58.2% vs avg$56.99
10mg
- 🇺🇸 Moglabs96
via Disclosed Labs · 23h ago
$8.20/mg -39.9% vs avg$82.00
10mg
- 🇺🇸 BioLongevity Labs96
✓ verified at source · 23h ago
$34.00/mg +149.4% vs avg$170
5mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 23h ago
$9.80/mg -28.1% vs avg$98.00
10mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 23h ago
$10.00/mg -26.7% vs avg$99.99
10mg
- 🇺🇸 Forge Performance Co.94
✓ verified at source · 23h ago
$7.00/mg -48.7% vs avg$70.00
10mg
no purityBuy code MERIT · 10% off - 🇺🇸 Peptide Plugs89
✓ verified at source · 23h ago
$6.00/mg -56% vs avg$60.00
10mg
- 🇺🇸 Simple Peptide85
✓ verified at source · 23h ago
$14.00/mg +2.7% vs avg$140
10mg
- Peptide Supply Co.83
via Disclosed Labs · 23h ago
$4.35/mg -68.1% vs avg$435
100mg
- 🇨🇳 Reta Peptide83
✓ verified at source · 23h ago
$13.50/mg -1% vs avg$135
10mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Cagrilintide
Get one email when the market actually moves — no newsletter, no noise.
About Cagrilintide
CAS
1415456-99-3
Molecular formula
C194H312N54O59S2
Sequence
KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP
Typical dose range
0.3–4.5 mg once weekly subcutaneous (Phase 2); 2.4 mg/week maintenance in Phase 3 REDEFINE/REIMAGINE trials
Half-life
~159–195 hours (~7–8 days)
COAs for Cagrilintide
120 third-party tests across 24 vendors. Each card links to the full report.
For
Cagrilintide
by EZ Peptides· batch EZP-CAG1006162026-02
For
Cagrilintide
by Ion Peptide· batch CGL5-06172026
For
Cagrilintide 10
by EZ Peptides· batch EZP-CAG10061620226-02
For
Cagrilintide
by Ion Peptide· batch CGL10-06252026
For
Cagrilintide
by Ion Peptide· batch CGL5-06242026
For
Cagrilintide
by Optima Supply· batch OS-2026-2806
For
Cagrilintide
by Hydro Research Peptides· batch HR-2026-3852
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0505152026-12
For
Cagrilintide
by EZ Peptides· batch EZP-CAG0505152026-12
For
Cagrilintide 5mg
by EZ Peptides· batch EZP-CAG05051520226-12
For
Cagrilintide
by Nox Amino· batch NA-CG0526-01
For
Cagrilintide
by Peptide Partners· batch SPL-3792
For
Cagrilintide
by NG Peptide· batch CG10-12
For
Cagrilintide
by NG Peptide· batch CG05-08
For
Cagrilintide
by Crush Research· batch CRCAG-5-2604-1
For
Cagrilintide
by Peptide Partners· batch CG202603
For
Cagrilintide
by Qihang Peptide· batch 4
For
Cagrilintide
by Amino Club· batch CAG0001
For
Cagrilintide
by Glacier Aminos· batch CAG5GA-02
For
Cagrilintide
by Ion Peptide· batch CAC10-03192026
For
Cagrliintide
by Ion Peptide· batch CAG10-03192026
For
Cagrilintide
by Mile High Compounds· batch CAG-010-MH-02
For
Cagrilintide
by Licensed Peptides· batch 032520261
For
Cagrilintide
by Pepsgpt· batch P-1457978-P
20 citations indexed for Cagrilintide
cohort · 2026
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials
Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
rct · 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
Background Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.
rct · 2026
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Background Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia.
rct · 2026
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide
Background and objectives Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes.
rct · 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
Background The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight.
review · 2026
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis
Background Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.